Stephanie Davis
Stock Analyst at Barclays
(0.57)
# 4,210
Out of 5,245 analysts
98
Total ratings
31.34%
Success rate
-109%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Overweight | $210 → $225 | $195.21 | +15.26% | 8 | Feb 11, 2026 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $19.57 | +129.94% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $4.94 | +1.21% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $19.94 | +276.13% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $7.39 | -5.28% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $2.64 | +127.27% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $3.95 | +381.01% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $274.91 | +5.49% | 2 | Nov 7, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $200.68 | -33.73% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $44.41 | +30.60% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $5.20 | -42.31% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $0.75 | $12.79 | -94.14% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $259.93 | -4.20% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $8.92 | +225.11% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $6.57 | +417.50% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $24.88 | +36.66% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $160.17 | +45.47% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $1.29 | +1,222.96% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $88.11 | -13.74% | 5 | Jun 7, 2022 |
Quest Diagnostics
Feb 11, 2026
Maintains: Overweight
Price Target: $210 → $225
Current: $195.21
Upside: +15.26%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $19.57
Upside: +129.94%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $4.94
Upside: +1.21%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $19.94
Upside: +276.13%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $7.39
Upside: -5.28%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $2.64
Upside: +127.27%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $3.95
Upside: +381.01%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $274.91
Upside: +5.49%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $200.68
Upside: -33.73%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $44.41
Upside: +30.60%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $5.20
Upside: -42.31%
Oct 10, 2024
Maintains: Underweight
Price Target: $0.75
Current: $12.79
Upside: -94.14%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $259.93
Upside: -4.20%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $8.92
Upside: +225.11%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $6.57
Upside: +417.50%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $24.88
Upside: +36.66%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $160.17
Upside: +45.47%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $1.29
Upside: +1,222.96%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $88.11
Upside: -13.74%